Targeting GPVI with glenzocimab in COVID-19 patients: Results from a randomized clinical trial.
Julien PottecherFrancois RaffiMartine Jandrot-PerrusSophie BinayAndrea ComenducciViolaine Desort-HeninDéborah FrançoisShahin GharakhanianMarilyn LabartAdeline MeilhocElie ToledanoYannick PletanGilles AvenardVictor H Satonull nullPublished in: PloS one (2024)
Therapeutic GPVI inhibition assessment during COVID-19 was conducted in response to a Public Health emergency. Glenzocimab in coagulopathic patients under therapeutic heparin was neither associated with increased bleeding, nor SAE. Clinical impact of glenzocimab on COVID-19 ARDS was not demonstrated. A potential role for GPVI inhibition in other types of ARDS deserves further experimentation. Glenzocimab is currently studied in stroke (ACTISAVE: NCT05070260) and cardiovascular indications.
Keyphrases
- public health
- sars cov
- acute respiratory distress syndrome
- atrial fibrillation
- end stage renal disease
- coronavirus disease
- extracorporeal membrane oxygenation
- ejection fraction
- newly diagnosed
- mechanical ventilation
- emergency department
- healthcare
- prognostic factors
- patient reported outcomes
- growth factor
- cancer therapy
- intensive care unit
- drug delivery
- subarachnoid hemorrhage
- brain injury
- cerebral ischemia